Congratulations to our 26 Novocure runners from Germany for successfully completing the “B2Run 2024” company running event in Munich! And a big thank you to all the colleagues who cheered for them along the 5.1km (3.1 mile) route through the beautiful Olympic Park. #B2Run #WeAreNovocure
Novocure
Herstellung medizinischer Geräte
Root, Switzerland 48.366 Follower:innen
Patient-forward: Aspiring to make a difference in cancer
Info
We are a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of our innovative therapy, Tumor Treating Fields. Our commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma and in the U.S. for the treatment of adult patients with malignant pleural mesothelioma. We have ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer and gastric cancer. Headquartered in Switzerland, Novocure has U.S. operations in Portsmouth, New Hampshire, Chesterbrook, Pennsylvania and New York City. Additionally, Novocure has offices in Canada, Germany, Jersey, Japan and Israel.
- Website
-
http://www.novocure.com
Externer Link zu Novocure
- Branche
- Herstellung medizinischer Geräte
- Größe
- 1.001–5.000 Beschäftigte
- Hauptsitz
- Root, Switzerland
- Art
- Kapitalgesellschaft (AG, GmbH, UG etc.)
- Gegründet
- 2000
- Spezialgebiete
- Medical Device, Oncology, Cancer, Glioblastoma und Neuro-Oncology
Orte
Beschäftigte von Novocure
Updates
-
We are at the British Neuro-Oncology Society (BNOS) Annual Meeting 2024 from July 17-19. We are delighted to support and participate in this multidisciplinary, collaborative event that brings together medical and non-medical experts who make a difference for patients with brain cancers. At Novocure, we are striving to extend survival in some of the most aggressive forms of cancer. #BNOS2024 #neurooncology #patientforward This message is intended for healthcare professionals in the UK only.
-
Today marks the sixth annual #GlioblastomaAwarenessDay, where patient advocates come together to support those living with GBM, remember those we have lost, and reaffirm our commitment to developing innovative treatments and, ultimately, a cure for this deadly disease that 15,000 Americans are diagnosed with each year. Mike Ambrogi, Novocure’s Senior Technology Fellow, sat down with Colin Gerner, CPA, President and Co-Founder of StacheStrong, a nonprofit that supports brain tumor patients and their loved ones through research and advocacy. Colin, who lost his older brother GJ to GBM, talked about the profound impact of being present and advocating for those battling this disease. Through our partnerships with patient advocacy organizations like StacheStrong and continued investment in research and development, we remain committed to supporting the brain tumor community and working towards a day where GBM, at long last, has a cure. https://lnkd.in/dDJt42QY #GBMDay #BTSM
-
When you build trust with your colleagues, you can help them innovate. That idea drives Zoey Binder, Manager, North America Compliance and Privacy, as she monitors for compliance risks, reviews policies and agreements, and educates colleagues on how to put policies into practice. A law school internship at Novocure sparked Zoey’s interest in compliance. She saw how she could use her legal and interpersonal skills to help a growing business solve problems in compliant ways. The team was welcoming, introducing her to a variety of legal, regulatory and compliance work. “At Novocure, people really foster a positive environment that encourages you to ask questions and learn,” Zoey said. She interned with us a second time and then joined full-time less than a year post-graduation. Today, Zoey connects with colleagues across North America, and she strives to help all (nearly 700) of them do their jobs better. Before someone pursues an idea, her team can help them understand important parameters to follow. “I love being at a company the size of Novocure because I feel like I can actually impact things,” she said. #WeAreNovocure #patientforward #trust #innovation
-
Glioblastoma (GBM) Awareness Day is coming up. On #GBMDay and every day, we recognize the impact of GBM, the most common primary brain cancer, on patients and caregivers. Read just a few of their stories: https://lnkd.in/eC5CUYVw
-
We will report financial results for the second quarter 2024 on Thursday, July 25, 2024, before the U.S. financial markets open. Learn more: https://lnkd.in/esqCy8BB
-
This June is the first Brain and Spine Metastasis Awareness Month, a reminder to talk about cancers that spread to the brain or spine, often leaving patients with limited treatment options. #MetsGetAwareness
-
Thank you, Hannah Schmidt, for courageously sharing your story! We are proud to be part of Portsmouth Pride. #pride #NewHampshire #WeAreNovocure
This weekend I had the privilege of speaking on my experience as a queer employee at Novocure. This year Novocure was the main stage sponsor for Portsmouth Pride. This is the beginning of our collaboration with Seacoast Outright, a non-profit supporting LGBT+ youth and who graciously organized this event. I look forward to more of these opportunities!
-
“It’s really about the patients,” says Anne Calixte de Lembeye, who leads our growing business in France. How does the team in France live our patient-forward mission? Enable individuals to take responsibilities. Embrace opportunities, and be perseverant. Today, our thriving team lives not only our mission but also our values of drive and trust. “We need to be proactive and trust people we work with,” Anne says. When Anne joined Novocure in 2020, we were just starting our journey to bring our Tumor Treating Fields (TTFields) therapy to patients in France. She was drawn to Novocure because of our innovative therapy and our patient-forward mission. The team in France grew, adding colleagues in market access and medical, then commercial and patient experience, with the objective to continue clinical development in aggressive solid tumors and support the patients with our patient experience team. To view job opportunities in France and around the globe, visit Novocure.com/careers. #patientforward #TTFields #oncology
-
Novocure hat dies direkt geteilt
The AACR-Novocure Cancer Research Grants provide $350,000 over three years to support independent investigators who are currently conducting innovative research focused on Tumor Treating Fields. Application deadline: July 1. Learn more: https://bit.ly/3VCcJdV
Ähnliche Seiten
Aktien
NVCR
NASDAQ
Verzögerung von 20 Minuten
18,48 $
-0,63 (-3,297 %)
- Aktiv
- 19
- Niedrig
- 18,25
- Hoch
- 19,29
Daten von Refinitiv
Mehr Informationen aufFinanzierung
Letzte Runde
Fremdkapital nach Börsengang100.000.000,00 $
Investor:innen
Pharmakon Advisors